Biosimilar facility

Pioneering Biogenerics

Alvogen’s sister company, Alvotech, is a uniquely positioned biopharmaceutical business that focuses purely on the biosimilar market with complete vertical integration from early R&D to commercial manufacturing. Current biosimilar assets include follow-on versions of seven leading monoclonal antibodies molecules, which will be brought to market after patent expiries.

Lab woman and man

Fully integrated development

Alvotech is focused on developing and bringing to market highest quality biosimilars. The current pipeline consists of six biosimilar monoclonal antibodies aimed at treating cancer, autoimmune, inflammatory and other diseases.



These products are developed in our four Research & Development centers located across Europe.



High-quality products will be manufactured in our state-of-the-art facility located in Reykjavik Iceland.



Partnership through Alvogen and key global players will be used to bring biosimilars to patients around the world.

Seringe line

In-house research and development

Alvotech is uniquely positioned with a fully integrated R&D and manufacturing engine, driven by best-in-class in-house research and development. Its state-of-the-art manufacturing facility fill finish capacity, situated in a patent-friendly location in Reykjavik, Iceland. Rasmus Rojkjaer leads the Alvotech team with over 200 colleagues who are passionate about transforming patients’ lives and bringing high-quality biopharmaceuticals to market.

Pioneering Biogenerics
We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. Learn more.